As per file enclosed
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venus Remedies Ltd reported strong FY2026 results with standalone revenue from operations of Rs 768.73 Cr, up 19.3% from Rs 644.47 Cr in FY2025. Net profit jumped 89% to Rs 99.31 Cr from Rs 52.55 Cr, while EPS grew to Rs 74.29 from Rs 39.32. Consolidated net profit was even stronger at Rs 102.78 Cr, up 127% YoY. EBITDA stood at Rs 155.37 Cr with positive operating cash flow of Rs 151.09 Cr. The board has recommended a final dividend of Rs 10 per share (100% on face value Rs 10), payable after shareholder approval at the 37th AGM on August 20, 2026. The statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated results. The company operates only in the pharmaceuticals segment with subsidiaries in Germany and Hungary.
The company delivered robust double-digit growth in both revenue and profit, exceeding 20% revenue growth and showing exceptional 89-127% profit growth. The clean audit opinion and proposed 100% dividend are positive signals for shareholders. The stock is likely to react positively to these results.